Tolga Memioğlu

Tolga Memioğlu

Auto-generated profile, based on publicly available information

Tolga Memioğlu

Department of Cardiology, Faculty of Medicine, Izzet Baysal Training and Research Hospital, Bolu Abant Izzet Baysal University, 14280 Bolu, Türkiye

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
TMTolga Memioglu
Tolga Memioglu
MÖMehmet ÖZYAŞAR
Mehmet ÖZYAŞAR

26 September 2012 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
SASelim Ayhan
Selim Ayhan
SOSerkan Ozturk
Serkan Ozturk
AAAytekin Alcelik
Aytekin Alcelik
MOMehmet Fatih Ozlu
Mehmet Fatih Ozlu
AEAlim Erdem
Alim Erdem
MYMehmet Yazici
Mehmet Yazici

8 August 2025 in Medicine
Verified
Journal Article
Open access
TMTolga Memioğlu
Tolga Memioğlu
MImehmet inanir
mehmet inanir
MDMurat DIRAMALI
Murat DIRAMALI
SKSalih Vahit Kiriş
Salih Vahit Kiriş
IGİbRahim Güven
İbRahim Güven
MÖMehmet ÖZYAŞAR
Mehmet ÖZYAŞAR
Coronary slow flow phenomenon (CSFP) is characterized by delayed coronary artery filling in the absence of significant obstructive coronary artery disease. It typically presents with angina-like chest pain and is defined by delayed opacification of the coronary arteries despite the absence of obstructive lesions. Although the pathophysiology of CSFP remains poorly understood, microvascular dysfunction, endothelial impairment, and systemic inflammation have been proposed as contributing factors. Hematological parameters, such as eosinophil and basophil counts, along with the eosinophil-to-basophil ratio (EBR) and monocyte-to-basophil ratio (MBR), have emerged as potential indicators of inflammation and cardiovascular pathology. This study aimed to investigate the association between these hematological markers and CSFP to enhance understanding and guide the development of diagnostic and therapeutic strategies. In this retrospective study, eosinophil, basophil, and monocyte counts, as well as derived ratios (EBR and MBR), were analyzed in 233 patients with CSFP and 229 controls who underwent coronary angiography but had normal coronary arteries. Blood samples were processed using an automated hematology analyzer. Group comparisons were performed using the independent samples t-test and Mann–Whitney U test (P < .05). Spearman correlation and logistic regression analyses were conducted to assess associations among variables. There was no statistically significant difference in the median age between the CSFP group (56.0 [IQR: 15.0]) and the control group (57.0 [IQR: 15.0]; P = .905). The CSFP group consisted predominantly of males (161 males, 72 females), whereas the control group had a higher proportion of females (152 females, 77 males), with a statistically significant difference in sex distribution (P < .001). Patients with CSFP exhibited significantly higher monocyte counts (P < .001), eosinophil counts (P = .012), EBR (P = .010), and MBR (P = .008) than controls. This study demonstrated significant differences in hematological parameters between patients with CSFP and controls. These findings suggest that specific hematological indices, particularly immune cell ratios, could serve as accessible, cost-effective biomarkers for CSFP. Further studies are needed to clarify their mechanistic roles and therapeutic relevance.

9 May 2025 in Medicine
Verified
Journal Article
Open access
MÖMehmet ÖZYAŞAR
Mehmet ÖZYAŞAR
TMTolga Memioğlu
Tolga Memioğlu
Circadian hypertension patterns, classified as dipper and non-dipper, influence cardiovascular risk and are linked to systemic inflammation. This study aimed to examine the relationship between hypertension phenotypes and inflammatory biomarkers. This retrospective cross-sectional study included 160 hypertensive patients with elevated office blood pressure (BP) who underwent 24-hour ambulatory BP monitoring and were categorized into dipper and non-dipper groups. Inclusion criteria comprised newly diagnosed, untreated individuals without hematological disorders, chronic inflammatory conditions, active infections, or moderate to severe chronic kidney disease. Inflammatory indices derived from complete blood counts were analyzed alongside demographic and clinical data. The cohort consisted of 79 dippers and 81 non-dippers, with a mean age of 46 ± 5 ± 11 ± 1 years. Non-dippers were more likely to be smokers ( P = .006) and exhibited significantly higher 24-hour, awake, and sleep systolic BPs and sleep diastolic BPs than dippers ( P = .001, P = .003, P < .001, and P < .001, respectively). Non-dippers also had elevated white blood cell counts, neutrophil (NEU) levels, neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) scores ( P < .001, P < .001, P < .001, P < .001, P < .001, P = .002, P < .001, and P < .001, respectively), while dippers exhibited higher lymphocyte counts ( P < .001). Logistic regression analyses indicated that NLR, dNLR, MLR, PLR, SII, and SIRI scores significantly predicted the inflammatory status of non-dipper hypertensive patients. Notably, dNLR demonstrated the highest specificity, sensitivity, and area under the curve values in the receiver operating characteristic analysis. This study identified significant differences in inflammatory status between dipper and non-dipper hypertensive groups, with inflammatory biomarkers strongly correlating with non-dipper hypertension. The dNLR score exhibited the strongest predictive value for non-dipper hypertension. Routine screening of inflammatory markers in clinical practice could facilitate early identification of at-risk patients and potentially improve treatment outcomes. However, further research is needed to validate these findings.

20 October 2025 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
TMTolga Memioğlu
Tolga Memioğlu
MIMehmet İnAnır
Mehmet İnAnır
KAKıvanç Argana
Kıvanç Argana
SKSalih Vahit Kiriş
Salih Vahit Kiriş
IGİbRahim Güven
İbRahim Güven
MÖMehmet Özyaşar
Mehmet Özyaşar
Background: Circadian variation in blood pressure, particularly the distinction between dipper and non-dipper profiles, plays a critical role in cardiovascular risk stratification. Although recent studies suggest that obesity may contribute to non-dipping patterns, the relationship remains controversial.Objective: To compare body mass index (BMI) between dipper and non-dipper hypertensive patients and to evaluate whether BMI can serve as a marker of non-dipping status.Methods: This retrospective observational study analyzed ambulatory blood pressure monitoring (ABPM) records of 200 patients (100 dippers and 100 non-dippers) who underwent 24-h ABPM using a validated Holter device. BMI values were calculated and compared between groups.Results: The distribution of sex did not differ significantly between dipper and non-dipper patients (p = 0.571). The mean BMI was significantly higher in the non-dipper group compared with the dipper group (30.75 ± 5.42 vs. 28.07 ± 5.09 kg/m2, p = 0.002). Non-dipper hypertensive patients demonstrated significantly higher BMI levels than dipper patients.Conclusions: These findings support the hypothesis that obesity may impair nocturnal blood pressure regulation and suggest that BMI could serve as a simple marker of non-dipping status. This indicates a potential association between increased BMI and a non-dipping blood pressure profile. Due to its retrospective design, this study cannot establish causality.

19 March 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
MÖMehmet ÖZYAŞAR
Mehmet ÖZYAŞAR
SÖSelçuk Öztürk
Selçuk Öztürk
TMTolga Memi̇oĞlu
Tolga Memi̇oĞlu
MImehmet inanir
mehmet inanir
Background: The sex-specific impact of micronutrient status on heart rate variability (HRV) in adults presenting with palpitations to cardiology outpatient clinics remains unclear. Thus, this study aimed to assess the demographic and biochemical determinants of HRV in a clinical cohort of patients presenting with complaints of palpitations. Methods: This retrospective study included 213 adults aged 18–65 years who presented with palpitations and underwent 24-hour Holter monitoring at our institution between 2023 and 2024. Patients with cardiovascular disease, known arrhythmias, chronic inflammatory conditions, renal dysfunction, or use of medications that affected autonomic function were excluded from the study. Demographic variables, laboratory parameters, and HRV indices were statistically analyzed. The standard deviation of all normal-to-normal intervals (SDNN) was the primary HRV parameter used in both univariate and multivariate linear regression analyses. Results: The SDNN was significantly lower in women and older adults. In the univariate analyses, age (β = –0.203; p = 0.003), male sex (β = 0.529; p < 0.001), ferritin, serum iron, folate, and Vitamin B12 were all associated with the SDNN. However, in the multivariable model, only male sex (β = 0.467; p < 0.001), iron-binding capacity (IBC) (β = –0.377; p < 0.001), and folate (β = 0.117; p = 0.037) remained independent predictors. Elevated IBC, reflecting functional iron deficiency, was strongly associated with a reduced SDNN, whereas higher folate levels were associated with better autonomic modulation. Conclusions: In patients presenting with palpitations, the SDNN is influenced by both demographic factors and biochemical markers of iron metabolism. Elevated IBC, reflecting alterations in iron metabolism and iron availability, was associated with impaired autonomic regulation, even in the absence of overt anemia. In contrast, adequate folate status appeared to support a more favorable autonomic function. These findings highlight the importance of integrating iron–vitamin assessment into the evaluation of autonomic function and underscore the need for prospective studies to determine whether correcting these abnormalities can improve HRV and clinical outcomes.